Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma

Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the stand...

ver descrição completa

Detalhes bibliográficos
Autores: Garcia-Guiñon, A, Charry, PA, Jimenez, M, Sarra, J, Delgado, I, de la Torre, LS, Santaliestra, M, Garcia-Pintos, M, Gonzalez, Y, Senin, A, Motlló, C, Abella, E, Cabezudo, E, Granell, M, Sancho, E, Herranz, MJ, Seres, Y, Gironella, M, Soler, JA, Marti-Tutusaus, JM, Ben Azaiz, R, de Larrea, CF
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p6233
Acesso em linha:https://i3pt.portalinvestigacion.com/publicaciones/6233
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85217774593&doi=10.1007%2Fs00277-025-06240-1&partnerID=40&md5=2a2c434cf68b6696526d2bfea01e73e6
Access Level:acceso abierto
Palavra-chave:Real-world
Carfilzomib, lenalidomide and dexamethasone
Relapsed/refractory multiple myeloma
Descrição
Resumo:Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having >= CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM.

Registos relacionados